US20210196676A1
University of Texas System
The present disclosure relates to the use of the sequiterpene lactones and Helenalin (H. tox) or its derivatives to treat viral infection and virally induced lesions, such as warts or wart-associated skin or mucosal lesion. A topical application, optionally using a skin covering such as gauze, a …